Published by Coherent Market Insights
Posted on September 28, 2021
Phosphodiesterase Enzyme (PDE) Inhibitors Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Phosphodiesterase Enzyme (PDE) Inhibitors Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/172
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals.
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers – cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all types of isoenzymes has provided possibilities for selective target therapies.
The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors have made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms is expected to result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors.
The global phosphodiesterase enzyme inhibitors market is therefore analyzed based on the drug class and application as follows:
Drug Class
Selective PDE inhibitors
PDE-1
PDE-2
PDE-3
PDE-4
PDE-5
Others
Non-selective PDE inhibitors
Application
Cardiovascular Disease
Respiratory Disease
Erectile Dysfunction
Pulmonary Hypertension
Benign Prostate Hyperplasia
Others
The global phosphodiesterase enzyme inhibitors market is majorly driven by development of PDE-5 inhibitors of blockbuster drugs in these segment.
Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook
The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is expected to benefit drugs in the long term and contribute to growth of the PDE inhibitors market.
In 2017, researchers from the John Hopkins University reviewed trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension.
PDE-5 inhibitor sildenafil developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit stroke patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death in men who have suffered one heart attack in their lifetime.
Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa is the first non-steroidal topical monotherapy for skin disorder.
Such product developments are expected to drive the global PDE inhibitors market growth in the near future.
Product developments in the U.S., Japan, and Europe are facilitating market growth. However, increasing number of product approvals in emerging economies such as India, China, Brazil, Russia, Argentina, and Indonesia are projected to favor demand in Asia Pacific and Latin America markets. Increasing healthcare expenditure and large population are some of the factors supporting growth of the PDE inhibitors market in these nations. However, stringent regulatory guidelines and challenges with product approvals are likely to hamper the market growth to some extent.
Buy This Premium Report Of Phosphodiesterase Enzyme (PDE) Inhibitors Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/172
In this study, the years considered to estimate the market size of Phosphodiesterase Enzyme (PDE) Inhibitors are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Phosphodiesterase Enzyme (PDE) Inhibitors Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Phosphodiesterase Enzyme (PDE) Inhibitors Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Phosphodiesterase Enzyme (PDE) Inhibitors Market Analysis By Supply And Consumption Demand Analysis To 2021 appeared first on Gatorledger.
Phosphodiesterase Enzyme (PDE) Inhibitors Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Phosphodiesterase Enzyme (PDE) Inhibitors Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/172
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals.
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers – cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all types of isoenzymes has provided possibilities for selective target therapies.
The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors have made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms is expected to result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors.
The global phosphodiesterase enzyme inhibitors market is therefore analyzed based on the drug class and application as follows:
Drug Class
Selective PDE inhibitors
PDE-1
PDE-2
PDE-3
PDE-4
PDE-5
Others
Non-selective PDE inhibitors
Application
Cardiovascular Disease
Respiratory Disease
Erectile Dysfunction
Pulmonary Hypertension
Benign Prostate Hyperplasia
Others
The global phosphodiesterase enzyme inhibitors market is majorly driven by development of PDE-5 inhibitors of blockbuster drugs in these segment.
Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook
The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is expected to benefit drugs in the long term and contribute to growth of the PDE inhibitors market.
In 2017, researchers from the John Hopkins University reviewed trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension.
PDE-5 inhibitor sildenafil developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit stroke patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death in men who have suffered one heart attack in their lifetime.
Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa is the first non-steroidal topical monotherapy for skin disorder.
Such product developments are expected to drive the global PDE inhibitors market growth in the near future.
Product developments in the U.S., Japan, and Europe are facilitating market growth. However, increasing number of product approvals in emerging economies such as India, China, Brazil, Russia, Argentina, and Indonesia are projected to favor demand in Asia Pacific and Latin America markets. Increasing healthcare expenditure and large population are some of the factors supporting growth of the PDE inhibitors market in these nations. However, stringent regulatory guidelines and challenges with product approvals are likely to hamper the market growth to some extent.
Buy This Premium Report Of Phosphodiesterase Enzyme (PDE) Inhibitors Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/172
In this study, the years considered to estimate the market size of Phosphodiesterase Enzyme (PDE) Inhibitors are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Phosphodiesterase Enzyme (PDE) Inhibitors Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Phosphodiesterase Enzyme (PDE) Inhibitors Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Phosphodiesterase Enzyme (PDE) Inhibitors Market Analysis By Supply And Consumption Demand Analysis To 2021 appeared first on Gatorledger.
Explore more articles in the Research Reports category
